<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000683206"><TermName>bavituximab</TermName><TermPronunciation>(ba-vih-TUK-sih-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of several types of cancer and infections caused by certain viruses. It binds to substances on the surface of tumor cells, certain viruses, and cells infected with a virus. The immune system detects bavituximab on the cells and the viruses and may destroy them. It is a type of monoclonal antibody and a type of targeted therapy agent. Also called Tarvacin.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000727856" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;bavituximab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000727855" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;bavituximab&quot;" language="es" id="_4"/><SpanishTermName>bavituximab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de varios tipos de cáncer e infecciones causadas por ciertos virus. Se une a las sustancias de la superficie de las células tumorales, ciertos virus y células infectadas por un virus. El sistema inmunitario detecta el bavituximab sobre las células y los virus, y podría destruirlos. Es un tipo de anticuerpo monoclonal y un tipo de sustancia que se usa en la terapia dirigida. También se llama Tarvacin.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2011-01-10</DateFirstPublished></GlossaryTerm>
